IQVIA HLDGS  DL-,01 logo

IQVIA HLDGS DL-,01 (QTS)

Market Closed
10 Jan, 20:00
196. 90
+0.3
+0.15%
- Market Cap
38.04 P/E Ratio
0% Div Yield
0 Volume
10.19 Eps
196.6
Previous Close
Day Range
196.9 196.9
Year Range
179.2 236
Earnings results expected in 28 days

Summary

QTS closed Friday higher at €196.9, an increase of 0.15% from Thursday's close, completing a monthly increase of 3.99% or €7.55. Over the past 12 months, QTS stock gained 3.99%.
QTS is not paying dividends to its shareholders.
The last earnings report, released on Oct 31, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Feb 12, 2025.
The stock of the company had never split.
The company's stock is traded on 9 different exchanges and in various currencies, with the primary listing on XBER (EUR).
Want to track QTS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

QTS Chart

FAQ

What Is the IQVIA HLDGS DL-,01(QTS) Stock Price Today?

The QTS stock price today is €196.90.

What Stock Exchange Does IQVIA HLDGS DL-,01 Trade On?

IQVIA HLDGS DL-,01 is listed and trades on the NYSE.

What Is the Stock Symbol for IQVIA HLDGS DL-,01?

The stock symbol for IQVIA HLDGS DL-,01 is "QTS".

Does IQVIA HLDGS DL-,01 Pay Dividends? What's The Current Dividend Yield?

QTS is not paying dividends to its shareholders.

What Is the IQVIA HLDGS DL-,01 Market Cap?

As of today, IQVIA HLDGS DL-,01 does not have a market cap available.

What is IQVIA HLDGS DL-,01 Earnings Per Share?

The IQVIA HLDGS DL-,01 EPS is 0.

What Is the Next IQVIA HLDGS DL-,01 Earnings Date?

IQVIA HLDGS DL-,01 will release its next earnings report on Feb 12, 2025.

Did IQVIA HLDGS DL-,01 had any splits?

No, IQVIA HLDGS DL-,01 has never had a stock split.

IQVIA HLDGS DL-,01 Profile

Diagnostics & Research Industry
Healthcare Sector
Mr. Ari Bousbib CEO
XBER Exchange
US46266C1053 ISIN
United States Country
88,000 Employees
- Last Dividend
- Last Split
9 May 2013 IPO Date

Overview

IQVIA Holdings Inc. is a cutting-edge company providing a suite of analytics, technology solutions, and clinical research services tailored for the life sciences sector. Operating globally, including the Americas, Europe, Africa, and the Asia-Pacific regions, IQVIA stands at the forefront of facilitating healthcare advancements. The company is organized into three main segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, catering to a diverse range of needs within the pharmaceutical, biotechnology, medical device and diagnostic, and consumer health industries. Originally known as Quintiles IMS Holdings, Inc., it underwent a rebranding to IQVIA Holdings Inc. in November 2017. With its headquarters in Durham, North Carolina, IQVIA continues to foster collaborations, including a notable partnership with argenx SE, to drive innovation and improve patient outcomes in healthcare.

Products and Services

  • Technology & Analytics Solutions
  • This segment offers a plethora of cloud-based applications coupled with implementation services designed explicitly for life sciences and healthcare providers. It helps in generating real-world evidence for healthcare decision-making and enhancing patient outcomes. Among these services are strategic and implementation consulting, encompassing advanced analytics and commercial processes outsourcing. Moreover, IQVIA provides critical metrics related to pharmaceutical sales, prescribing trends, medical treatments, and various promotional activities, not to mention detailed sales or prescribing data at different geographical levels.

  • Research & Development Solutions
  • This division supports the full spectrum of clinical trial and research development, including project management, clinical monitoring, and patient-centric solutions. It assists in strategic planning and design for clinical trials, central laboratory services, genomic, bioanalytical, ADME (Absorption, Distribution, Metabolism, and Excretion), discovery, and vaccine and biomarker laboratory services, thereby accelerating the journey from early-stage research to market-ready products.

  • Contract Sales & Medical Solutions
  • Focused on enhancing engagement with healthcare providers and patients, this segment delivers comprehensive services spanning from health care provider engagement to scientific strategy and medical affairs. These solutions aim to optimize interactions between the medical community and the industry to foster a deeper understanding and adoption of advanced healthcare solutions and treatments.

Contact Information

Address: 2400 Ellis Road
Phone: 919 998 2000